Please assess the completion status of the following clinical trial:

Trial Title: Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pts have confirmed diagnosis of recurrent/progressive WHO gr III \& IV MG~* Age \>18 rs~* Interval of \>4 wks since prior surgery~* Interval of \>4 wks since prior XRT/chemo, unless there is unequivocal evidence of progressive disease \& pts have recovered from all anticipated toxicity of most recent therapy;~* Karnofsky performance status score \>60~* Hematocrit \>29 percent, ANC \>1,500 cells/microliter, platelets \>100,000 cells/microliter~* Serum creatinine \<1.5 mg/dl, BUN \<25 mg/dl, serum SGOT \& bilirubin \<1.5 x ULN~* For pts on corticosteroids, they have been on astable dose for 1wk prior to entry~* Signed informed consent approved by IRB prior to pt entry~* If sexually active, pts must agree to take contraceptive measures for duration of treatments.~Exclusion Criteria:~* Prior therapy w either bevacizumab/etoposide~* \>3 prior recurrences~* Pregnancy/breast feeding~* Co-medication w immuno-suppressive agents other than corticosteroids including but not limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil~* Evidence of CNS hemorrhage on baseline MRI on CT scan~* Pts who require therapeutic anti-coagulation~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics \& psychiatric illness/social situations that would limit compliance w study requirements, or disorders associated w significant immunocompromised state~* Pts w another primary malignancy that has required treatment \<past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + Etoposide (Type: EXPERIMENTAL): Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).